Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m2 IV) and cyclophosphamide (600 mg/m2 IV). All patients had been refractory to prior radiotherapy and hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46\%) achieved an objective response: 1 complete response (8\%) and 5 partial responses (38\%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.
Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide / E., Campora; A., Vidali; S., Mammoliti; N., Ragni; Conte, Pierfranco. - In: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. - ISSN 0392-2936. - STAMPA. - 11:(1990), pp. 181-183.
Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide.
CONTE, Pierfranco
1990
Abstract
Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m2 IV) and cyclophosphamide (600 mg/m2 IV). All patients had been refractory to prior radiotherapy and hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46\%) achieved an objective response: 1 complete response (8\%) and 5 partial responses (38\%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
